Search form

Search form

More psoriasis patients who took Celgene's experimental drug apremilast experienced improvements in symptoms compared with patients who took a placebo, a late-stage trial found. Celgene plans to submit the drug for FDA approval this year.

Related Summaries

A midstage study found that Celgene's experimental drug apremilast was effective in improving symptoms for patients with Behcet's syndrome. According to the study, more patients who took apremilast were free from oral and genital ulcers after 12 weeks of treatment than those who took a placebo.

Celgene's experimental drug apremilast significantly improved signs and symptoms of psoriatic arthritis including joint pains in previously untreated patients compared with a placebo, a Phase III trial found. The improvements in symptoms persisted through a year of treatment. The FDA could decide on approval in March.

A late-stage study found that most psoriatic arthritis patients who took Celgene's investigational drug apremilast experienced significant improvements in signs and symptoms after 52 weeks of treatment. Celgene plans to submit apremilast for both psoriatic arthritis and psoriasis indications in Europe this year. An application has been submitted to the FDA for psoriatic arthritis.

Celgene's apremilast treated moderate to severe psoriasis in 41% of patients, compared with 6% for those who received placebo, during a Phase II clinical trial. The findings put Celgene on track to conduct late-stage studies of the drug next year.